Commenting on the news, GeneThera Chairman Dr. Tony Milici, M.D., Ph.D., stated, "We are very excited about the signing of this agreement with STC.UNM. It is our intention to initiate clinical trials for the E. coli vaccine in the near future. Our goal is to take the vaccine to market as soon as possible. E. coli infection represents a great threat for the food industry and it is no longer limited to beef as recent episodes have shown. Every year more than 70 people die from E. coli infection. Children in particular are more vulnerable to this infection. A recent study estimated the annual cost of E. coli O157:H7 illnesses to be $405 million (in 2003 dollars), which included $370 million for premature deaths, $30 million for medical care, and $5 million for lost productivity."
Dr. Milici went on to say that "the CDC has estimated that 85% of E. coli O157:H7 infections are food borne in origin. In fact, consumption of any food or beverage that becomes contaminated by animal (especially cattle) manure can result in contracting the disease."
The vaccine has already passed the initial animal trials, and is on the fast track for phase 2 clinical trials according to Dr. Milici.
STC.UNM President & CEO, Lisa Kuuttila, stated that "STC looks forward to the next stage of development enabled by this agreement. GeneThera will be conducting an important trial of the vaccine."
GeneThera hopes to complete clinical trials within the next 9-12 months. That could mean a viable vaccine to help prevent E. coli infections could be available for worldwide distribution to all commercial cattle producers in the very near future.
ABOUT GENETHERA, INC.
GeneThera, Inc., is a molecular biotechnology company
|SOURCE GeneThera, Inc.|
Copyright©2008 PR Newswire.
All rights reserved